Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07019012 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is designed to evaluate the change in glycated hemoglobin (HbA1c) levels from baseline to 24 weeks after the combination therapy of cofrogliptin, metformin and SGLT2i (dapagliflozin) in type 2 diabetes mellitus (T2DM) patients with poor control of glucose level by metformin and SGLT2i combination therapy.
Trial Details
NCT Number NCT07019012
Lead Sponsor Huazhong University of Science and Technology
Collaborators: Renmin Hospital of Wuhan University, Wuhan Central Hospital, Taihe Hospital, Xiangyang No.1 People's Hospital, The First Affiliated Hospital of Nanchang University
Conditions
(from sponsor)		 T2DM
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov